Membranous Nephropathy Diagnostic Advancements and Novel Biomarkers in 2026 Expanding the Portfolio of Autoantibodies Beyond Traditional Testing
The landscape of glomerular diseases is undergoing a radical transformation as we move into 2026. For decades, the identification of the PLA2R receptor was the gold standard, but recent clinical updates have introduced a variety of new target antigens such as THSD7A, NELL1, and EXT1. These biomarkers allow clinicians to...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
